Delivery systems for antisense oligonucleotides

Pharmacology and Therapeutics

Volumn 87, Issue 2-3, 2000, Pages 255-277

  Garcia Chaumont, Ch ^a   Seksek, O ^a   Grzybowska, J ^b   Borowski, E ^b   Bolard, J ^a  

^a EUROPEAN SPACE AGENCY   (France)

^b GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Amphotericin B; Antisense; Cationic lipids; Gene therapy; Liposomes; Oligonucleotides

Indexed keywords

1,2 BIS(OLEOYLOXY) 3 (TRIMETHYLAMMONIUM)PROPANE; 1,2 DIOLEOYLGLYCERO 3 PHOSPHATIDYLETHANOLAMINE; 2,3 DIOLEOYLOXY N [2 (SPERMINECARBOXAMIDO)ETHYL] N,N DIMETHYL 1 PROPANAMINIUM TRIFLUOROACETATE; 3BETA [N (N',N'' DIMETHYLAMINOETHANE)CARBAMOYL]CHOLESTEROL; AMPHOTERICIN B 3' DIMETHYLAMINOPROPYLAMIDE; AMPHOTERICIN B DERIVATIVE; ANTISENSE OLIGODEOXYNUCLEOTIDE; CETRIMIDE; DIMYRISTOOXYPROPYLDIMETHYLHYDROXYETHYLAMMONIUM BROMIDE; DIOACTADECYLDIMETHYLAMMONIUM BROMIDE; DIOCTADECYLAMIDOGLYCYLSPERMINE; DRUG CARRIER; GS 2888; LIPOSOME; N (ALPHA TRIMETHYLAMMONIOACETYL)DIDODECYL DEXTRO GLUTAMATE CHLORIDE; N [1 (2,3 DIOLEOXY)PROPYL] N,N,N, TRIMETHYLAMMONIUM CHLORIDE; N DEXTRO ORNITHYLAMPHOTERICIN B 3' DIMETHYLAMINOPROPYLAMIDE; PEPTIDE; POLY(AMIDOAMINE); POLYELECTROLYTE; POLYENE ANTIBIOTIC AGENT; POLYETHYLENEIMINE; POLYLYSINE; SPERMINE CHOLESTEROL; STREPTOLYSIN O; UNCLASSIFIED DRUG;

CELL MEMBRANE PERMEABILITY; COMPLEX FORMATION; CONFERENCE PAPER; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENCAPSULATION; ENDOCYTOSIS; ENDOSOME; LIPID SOLUBILITY; MICELLE; MOLECULAR INTERACTION; NONHUMAN; NUCLEIC ACID PROBE; PRIORITY JOURNAL; SERUM;

AMPHOTERICIN B; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; GENE THERAPY; HUMAN; LIPOSOMES; MICELLES; OLIGONUCLEOTIDES, ANTISENSE; PERMEABILITY; SUPPORT, NON-U.S. GOV'T;

EID: 0033796894     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(00)00062-0     Document Type: Conference Paper

References (203)

1. Agrawal, S., & Crooke, S. T. (Eds.) (1998). Antisense Research and Application. Handbook of Experimental Pharmacology. Berlin, New York: Springer.
2. Agrawal S., Iyer R.P. Perspectives in antisense therapeutics. Pharmacol Ther. 76:1997;151-160.
3. Agrawal S., Zhao Q. Antisense therapeutics. Curr Opin Chem Biol. 2:1998;519-528.
4. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci. 18:1997;12-18.
5. Akhtar S., Juliano R.L. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 2:1992;139-144.
6. Akhtar S., Lewis K.J. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres. Int J Pharm. 151:1997;57-67.
7. Akhtar S., Basu S., Wickstrom E., Juliano R.L. Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res. 19:1991;5551-5559.
8. Alahari S.K., Dean N.M., Fisher M.H., Delong R., Manoharan M., Tivel K.L., Juliano R.L. Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5′cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol. 50:1996;808-819.
9. Alahari S.K., Delong R., Fisher M.H., Dean N.M., Viliet P., Juliano R.L. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression. J Pharmacol Exp Ther. 286:1998;419-428.
10. Aliño S.F., Crespo J., Tarrasón G., Blaya C., Adán J., Escrig E., Benet M., Crespo A., Piulats J. Oligonucleotide-entrapped immunoliposome delivered by mini-osmotic pump improves the survival of SCID mice bearing human leukemia. Tumor Target. 4:1999;20-28.
11. Aoki M., Morishita R., Higaki J., Moriguchi A., Kida I., Hayashi S.I., Matsushita H., Kaneda Y., Ogihara T. In vivo transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method. Biochem Biophys Res Commun. 231:1997;540-545.
12. Arima H., Aramaki Y., Tsuchiya S. Effects of oligodeoxynucleotides on the physicochemical characteristics and cellular uptake of liposomes. J Pharm Sci. 86:1997;438-442.
13. Bachmann A.S., Surovoy A., Jung G., Moelling K. Integrin receptor-targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides. J Mol Med. 76:1998;126-132.
14. Bailey A.L., Cullis P.R. Membrane fusion with cationic liposomes. effects of target membrane lipid composition Biochemistry. 36:1997;1628-1634.
15. Beltinger C., Saragovi H.U., Smith R.M., Lesauteur L., Shah N., Dedionisio L., Christensen L., Raible A., Jarett L., Gewirtz A.M. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest. 95:1995;1814-1823.
16. Benimetskaya L., Loike J.D., Khaled Z., Loike G., Silverstein S.C., Cao L., El Khoury J., Cai T., Stein C.A. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nature Med. 3:1997;414-420.
17. Benimetskaya L., Takle G.B., Vilenchik M., Lebedeva I., Miller P., Stein C.A. Cationic porphyrins. novel delivery vehicles for antisense oligodeoxynucleotides Nucleic Acids Res. 26:1998;5310-5317.
18. Bennett C.F. Use of cationic lipid complexes for antisense oligonucleotide delivery. Stein C.A., Krieg A.M. Applied Antisense Oligonucleotide Technology. 1998;129-145 Wiley-Liss, New York.
19. Bennett C.F., Chiang M.Y., Chan H., Shomaker J.E., Mirabelli C.K. Cationic lipids enhance uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 41:1992;1023-1033.
20. Bennett C.F., Condon T.P., Grimm S., Chan H., Chiang M.-Y. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol. 152:1994;3530-3540.
21. Bennett C.F., Zuckerman J.E., Kornbrust D., Sasmor H., Leeds J.M., Crooke S.T. Pharmacokinetics in mice of a 3H-labeled phosphorothioate oligonucleotide formulated in the presence and absence of a cationic lipid. J Controlled Release. 41:1996;121-130.
22. Bennett C.F., Mirejovsky D., Crooke R.M., Tsai Y.J., Felgner J., Sridhar C.N., Wheeler C.J., Felgner P.L. Structural requirements for cationic lipid mediated phosphorothioate oligonucleotides delivery to cells in culture. J Drug Target. 5:1998;149-162.
23. Berton M., Sixou S., Kravtzoff R., Dartigues C., Imbertie L., Allal C., Favre G. Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular Bio Vector (SMBV). Biochim Biophys Acta. 1355:1997;7-19.
24. Bielinska A., Kukowska-Latallo J.F., Johnson J., Tomalia D.A., Baker J.R.J. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res. 24:1996;2176-2182.
25. Biessen E.A.L., Vietsch H., Kuiper J., Bijsterbosch M.K., Vanberkel T.J.C. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol. 53:1998;262-269.
26. Biessen E.A., Vietsch H., Rump E.T., Fluiter K., Kuiper J., Bijsterbosch M.K., van Berkel T.J. Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo. Biochem J. 340:1999;783-792.
27. Bijsterbosch M.K., Manoharan M., Rump E.T., De Vrueh R.L.A., van Veghel R., Tivel K.L., Biessen E.A.L., Bennett C.F., Cook P.D., van Berkel T.J.C. In vivo fate of phosphorothioate antisense oligodeoxynucleotides. predominant uptake by scavenger receptors on endothelial liver cells Nucleic Acids Res. 25:1997;3290-3296.
28. Bilbao G., Contreras J.L., Curiel D.T. Advances in cancer gene therapy. Expert Opin Ther Patents. 9:1999;711-735.
29. Binet A., Bolard J. Recovery of hepatocytes from attack by the pore former amphotericin B. Biochem J. 253:1988;435-440.
30. Blanc I., Bueno Da Costa H.-H., Bolard J., Saint-Pierre Chazalet M. Oligonucleotide delivery by a cationic derivative of the polyene antibiotic amphotericin B. I. Interaction of oligonucleotide/vector as studied by optical spectroscopy and electron microscopy. Biochim Biophys Acta. 1464:2000;299-308.
31. Bonfils E., Depierreux C., Midoux P., Thuong N.T., Monsigny M., Roche A.C. Drug targeting. synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates Nucleic Acids Res. 20:1992;4621-4629. a.
32. Bonfils E., Mendes C., Roche A.C., Monsigny M., Midoux P. Uptake by macrophages of biotinylated oligo-alpha-deoxythymidylate by using mannosylated steptavidin. Bioconjug Chem. 3:1992;277-282. b.
33. Bongartz J.P., Aubertin A.M., Milhaud P.G., Lebleu B. Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res. 22:1994;4681-4688.
34. Boukhnikachvili T., Aguerre-Chariol O., Airiau M., Lesieur S., Ollivon M., Vacus J. Structure of in-serum transfecting DNA-cationic lipid complexes. FEBS Lett. 409:1997;188-194.
35. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.J., Scherman D., Demeneix B., Behr J.-P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo. polyethylenimine Proc Natl Acad Sci USA. 92:1995;7297-7301.
36. Boutorine A.S., Kostina E.V. Reversible covalent attachment of cholesterol to oligodeoxyribonucleotides for studies of the mechanisms of their penetration into eucaryotic cells. Biochimie. 75:1993;35-41.
37. Bunnell B.A., Askari F.K., Wilson J.M. Targeted delivery of antisense oligonucleotides by molecular conjugates. Somat Cell Mol Genet. 18:1992;559-569.
38. Burch R.M., Mahan L.C. Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice. J Clin Invest. 88:1991;1190-1196.
39. Capaccioli S., Dipasquale G., Mini E., Mazzei T., Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun. 197:1993;818-825.
40. Chaudhuri G. Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Biochem Pharmacol. 53:1997;385-391.
41. Chavany C., Le Doan T., Couvreur P., Puisieux F., Hélène C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res. 9:1992;441-449.
42. Chavany C., Saison-Behmoaras T., Le Doan T., Puisieux F., Couvreur P., Hélène C. Adsorption of oligonucleotide onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm Res. 11:1994;1370-1378.
43. Chéron M., Cybulska B., Mazerski J., Grzybowska J., Czerwinski A., Borowski E. Quantitative structure-activity relationships in amphotericin B derivatives. Biochem Pharmacol. 37:1988;827-836.
44. Chin D.J., Green G.A., Zon G., Szoka F.C., Straubinger R.M. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol. 2:1990;1091-1100.
45. Chu C.J., Szoka F.C. pH-sensitive liposomes. J Liposome Res. 4:1994;361-395.
46. Citro G., Perrotti D., Cucco C., D'Agnano I., Sacchi A., Zupi G., Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA. 89:1992;7031-7035.
47. Citro G., Szczylik C., Ginobbi P., Zupi G., Calabretta B. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br J Cancer. 69:1994;463-467.
48. Clarenc J.P., Degols G., Leonetti J.P., Milhaud P., Lebleu B. Delivery of antisense oligonucleotides by poly(L-lysine) conjugation and liposome encapsulation. Anticancer Drug Des. 8:1993;81-94.
49. Cleek R.L., Rege A.A., Denner L.A., Eskin S.G., Mikos A.G. Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles. J Biomed Mater Res. 35:1997;525-530.
50. Colige A., Sokolov B.P., Nugent P., Baserga R., Prockop D.J. Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. Biochemistry. 32:1993;7-11.
51. Compagnon B., Milhaud P., Bienvenue A., Philippot J.R. Targeting of poly(rI)-poly(rC) by fusogenic (F protein) immunoliposomes. Exp Cell Res. 200:1992;333-338.
52. Crooke S.T., Bennett F. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol. 36:1996;107-129.
53. Dean N.M., McKay R., Condon T.P., Bennett C.F. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem. 269:1994;16416-16424.
54. Degols G., Leonetti J.P., Mechti N., Lebleu B. Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene. Nucleic Acids Res. 19:1991;945-948.
55. De Oliveira M.C., Fattal E., Couvreur P., Lesieur P., Bourgaux C., Ollivon M., Dubernet C. pH-sensitive liposomes as a carrier for oligonucleotides. a physico-chemical study of the interaction between DOPE and a 15-mer oligonucleotide in quasi-anhydrous samples Biochim Biophys Acta. 1372:1998;301-310.
56. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem. 271:1996;18188-18193.
57. Deshpande D., Blezinger P., Pillai R., Duguid J., Freimark B., Rolland A. Target specific optimization of cationic lipid-based systems for pulmonary gene therapy. Pharm Res. 15:1998;1340-1347.
58. de Smidt P.C., Le Doan T., de Falco S., van Berkel T.U. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies tissue distribution. Nucleic Acids Res. 19:1991;4695-4700.
59. Ebbinghaus S.W., Vigneswaran N., Miller C.R., Chee-Awai R.A., Mayfield C.A., Curiel D.T., Miller D.M. Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes. Gene Ther. 3:1996;287-297.
60. Etore F., Tenu J.P., Teiger E., Adnot S., Lonchampt M.O., Pirotzki E., Le Doan T. Sequence dependency of the internalization and distribution of phosphorothioate oligonucleotides in vascular smooth muscle cells. Biochem Pharmacol. 55:1998;1465-1473.
61. Falkowski L., Jarzebski A., Stefanska B., Bylec E., Borowski E. The synthesis of amides of polyene macrolide antibiotics. J Antibiot. 33:1980;103-104.
62. Fattal E., Vauthier C., Aynie I., Nakada Y., Lambert G., Malvy C., Couvreur P. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J Controlled Release. 53:1998;137-143.
63. Felgner P.L. Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides. Adv Drug Delivery Rev. 5:1990;163-187.
64. Felgner P.L., Ringold G.M. Cationic liposome-mediated transfection. Nature. 337:1989;387-388.
65. Field A.K. Viral targets for antisense oligonucleotides. a mini review Antiviral Res. 37:1998;67-81.
66. Fisher T.L., Terhorst T., Cao X., Wagner R.W. Intracellular disposition and metabolism of fluorescently-labeled unmodified and modified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res. 21:1993;3857-3865.
67. Flynn S.M., George S.T., White L., Devonish W., Takle G.B. Water-soluble, meso-substituted cationic porphyrins - a family of compounds for cellular delivery of oligonucleotides. Biotechniques. 26:1999;736-746.
68. Gao W.Y., Storm C., Egan W., Cheng Y.C. Cellular pharmacology of phosphorothioate homooligonucleotides in human cells. Mol Pharmacol. 43:1992;45-50.
69. Garcia-Chaumont C., Seksek O., Jollès, Bolard J. A cationic derivative of amphotericin B as a novel delivery system for antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. in press:2000.
70. Ginobbi P., Geiser T.A., Ombres D., Citro G. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. Anticancer Res. 17:1997;29-36.
71. Goto T., Suzuki Y., Wada A., Nozawa I., Sero S., Kawai S., Mizushima Y. A novel approach for gene medicine; synthetic poly-L-lysine/serine copolymer enhances bioactivity of antisense oligonucleotides. Nucleosides & Nucleotides. 16:1997;1609-1615.
72. Gray G.D., Wickstrom E. Rapid measurement of modified oligonucleotide levels in plasma samples with a fluorophore specific for single-stranded DNA. Antisense Nucleic Acid Drug Dev. 7:1997;159-165.
73. Guy-Caffey J.K., Bodepudi V., Bishop J.S., Jayaraman K., Chaudhary N. Novel polyaminolipids enhance the cellular uptake of oligonucleotides. J Biol Chem. 270:1995;31391-31396.
74. Haller H., Dragun D., Miethke A., Park J.K., Weis A., Lippoldt A., Gross V., Luft F.C. Antisense oligonucleotides for ICAM-1 attenuate reperfusion injury and renal failure in the rat. Kidney Int. 50:1996;473-480.
75. Hangeland J.J., Flesher J.E., Deamond S.F., Lee Y.C., Ts O.P., Frost J.J. Tissue distribution and metabolism of the [32P]-labeled oligodeoxynucleoside methylphosphonate-neoglycopeptide conjugate, [YEE(ah-GalNAc)3]-SMCC-AET-pUmpT7, in the mouse. Antisense Nucleic Acid Drug Dev. 7:1997;141-149.
76. Hanss B., Lealpinto E., Bruggeman L.A., Copeland T.D., Klotman P.E. Identification and characterization of a cell membrane nucleic acid channel. Proc Natl Acad Sci USA. 95:1998;1921-1926. a.
77. Hanss B., Stein C.A., Klotman P.E. Cellular uptake and biodistribution of oligodeoxynucleotides. Stein C.A., Krieg A.M. Applied Antisense Oligonucleotide Technology. 1998;111-127 Wiley-Liss, New York. b.
78. Hartmann G., Krug A., Bidlingmaier M., Hacker U., Eigler A., Albrecht R., Strasburger C.J., Endres S. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J Pharmacol Exp Ther. 285:1998;920-928.
79. Hartsel S., Bolard J. Amphotericin B. new life for an old drug Trends Pharmacol Sci. 17:1996;445-449.
80. Hélin V., Gottikh M., Mishal Z., Subra F., Malvy C., Lavignon M. Cell cycle-dependent distribution and specific inhibitory effect of vectorized antisense oligonucleotides in cell culture. Biochem Pharmacol. 58:1999;95-107.
81. Ho P.T.C., Parkinson D.R. Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol. 24:1997;187-202.
82. Huang C.Y., Uno T., Murphy J.E., Lee S., Hamer J.D., Escobedo J.A., Cohen F.E., Radhakrishnan R., Dwarki V., Zuckermann R.N. Lipitoids - novel cationic lipids for cellular delivery of plasmid DNA in vitro. Chem Biol. 5:1998;345-354.
83. Hughes J.A., Aronsohn A.I., Avrutskaya A.V., Juliano R.L. Evaluation of adjuvants that enhance the effectiveness of antisense oligonucleotides. Pharm Res. 13:1996;404-410.
84. Israel Z.H., Domb A.J. Polymers in gene therapy. antisense delivery systems Polym Adv Technol. 9:1998;799-805.
85. Iversen P.L., Zhu S., Meyer A., Zon G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev. 2:1992;211-222.
86. Jääskeläinen I., Mönkkönen J., Urtti A. Oligonucleotide-cationic liposome interaction. A physicochemical study. Biochim Biophys Acta. 1195:1994;115-123.
87. Jääskeläinen I., Sternberg B., Monkkonen J., Urtti A. Physicochemical and morphological properties of complexes made of cationic liposomes and oligonucleotides. Int J Pharm. 167:1998;191-203.
88. Juliano R.L., Alahari S., Yoo H., Kole R., Cho M. Antisense pharmacodynamics. critical issues in the transport and delivery of antisense oligonucleotides Pharm Res. 16:1999;494-502.
89. Kabanov A.V., Vinogradov S.V., Ovcharenko A.V., Krivonos A.V., Melik-Nubarov N.S., Kiselev V.I., Severin E.S. A new class of antivirals. antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells FEBS Lett. 259:1990;327-330.
90. Kabanov A.V., Vinogradov S.V., Suzdaltseva Y.G., Alakhov V.Y. Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug Chem. 6:1995;639-643.
91. Kanamaru T., Takagi T., Takakura Y., Hashida M. Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes. J Drug Target. 5:1998;235-246.
92. Kataoka K., Togawa H., Harada A., Yasugi K., Matsumoto T., Katayose S. Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in physiological saline. Macromolecules. 29:1996;8556-8557.
93. Krieg A.M., Gmelig-Meyling F., Gourley M.F., Kisch W.J., Chrisey L.A., Steinberg A.D. Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. Antisense Res Dev. 1:1991;161-171.
94. Laktionov P.P., Dazard J.E., Vives E., Rykova E.Y., Piette J., Vlassov V.V., Lebleu B. Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res. 27:1999;2315-2324.
95. Lappalainen K., Urrti A., Söderling E., Jääskeläinen I., Syrjänen K., Syrjänen S. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim Biophys Acta. 1196:1994;201-208.
96. Lasic, D. D. (Ed.) (1997). Liposomes in Gene Delivery. Boca Raton, FL: CRC Press.
97. Lavigne C., Thierry A.R. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system. Biochem Biophys Res Commun. 237:1997;566-571.
98. Legendre J.Y., Szoka F.C. Jr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes. comparison with cationic liposomes Pharm Res. 9:1992;1235-1242.
99. Legendre J.Y., Trzeciak A., Bohrmann B., Deuschle U., Kitas E., Supersaxo A. Dioleoylmelittin as a novel serum-insensitive reagent for efficient transfection of mammalian cells. Bioconjug Chem. 8:1997;57-63.
100. Lemaitre M., Bayard B., Lebleu B. Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site. Proc Natl Acad Sci USA. 84:1987;648-652.
101. Leonetti J.P., Machy P., Degols G., Lebleu B., Leserman L. Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci USA. 87:1990;2448-2451.
102. Leonetti J.-P., Degols G., Clarenc J.-P., Mechti N., Lebleu B. Cell delivery and mechanisms of action of antisense oligonucleotides. Prog Nucleic Acid Res Mol Biol. 44:1993;143-165.
103. Letsinger R.L., Zhang G., Sun D.K., Ikeuchi T., Sarin P.S. Cholesteryl-conjugated oligonucleotide. synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture Proc Natl Acad Sci USA. 86:1989;6553-6558.
104. Lewis J.G., Lin K.-Y., Kothavale A., Flanagan W.M., Matteucci M.D., DePrince R.B., Mook R.A.J., Wayne Hendren R., Wagner R.W. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA. 93:1996;3176-3181.
105. Lewis K.J., Irwin W.J., Akhtar S. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides. characterization of P(LA-GA) copolymer microspheres in vitro J Drug Target. 5:1998;291-302.
106. Li B., Hughes J.A., Philipps M.I. Uptake and efflux of intact antisense phosphorothioate deoxyoligonucleotide directed against angiotensin receptors in bovine adrenal cells. Neurochem Int. 31:1997;393-403.
107. Liang W.W., Shi X., Deshpande D., Malanga C.J., Rojanasakul Y. Oligonucleotide targeting to alveolar macrophages by mannose receptor-mediated endocytosis. Biochim Biophys Acta. 1279:1996;227-234.
108. Litzinger D.C., Huang L. Phosphatidylethanolamine liposomes. drug delivery, gene transfer and immunodiagnostic applications Biochim Biophys Acta. 1113:1992;201-227.
109. Litzinger D.C., Brown J.M., Wala I., Kaufman S.A., Van G.Y., Farrell C.L., Collins D. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim Biophys Acta. 1281:1996;139-149.
110. Loke S.L., Stein C., Zhang X., Avigan M., Cohen J., Neckers L.M. Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic cells in culture by liposome fusion. specific reduction in c-myc protein expression correlates with inhibition of cell growth and DNA synthesis Curr Top Microbiol Immunol. 141:1988;282-289.
111. Loke S.L., Stein C.A., Zhang X.H., Mori K., Nakanishi M., Subasinghe C., Cohen J.S., Neckers L.M. Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA. 86:1989;3474-3478.
112. Lu X.-M., Fischman A.J., Jyawook S.L., Hendricks K., Tompkins R.G., Yarmush M.L. Antisense DNA delivery in vivo. liver targeting by receptor-mediated uptake J Nucl Med. 35:1994;269-275.
113. Lukacs G.L., Haggie P., Seksek O., Lechardeur D., Freedman N., Verkman A.S. Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem. 275:2000;1625-1629.
114. Ma D.D.F., Wei A.-Q. Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes. Leuk Res. 20:1996;925-930.
115. Ma L., Calvo F. Recent status of the antisense oligonucleotide approaches in oncology. Fundam Clin Pharmacol. 10:1996;97-115.
116. Mahato R.I., Takemura S., Akamatsu K., Nishikawa M., Takakura Y., Hashida M. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem Pharmacol. 53:1997;887-895.
117. Malewicz B., Jenkin H.M., Borowski E. Dissociation between the induction of potassium efflux and cytostatic activity of polyene macrolides in mammalian cells. Antimicrob Agents Chemother. 17:1980;699-706.
118. Marcusson E.G., Bhat B., Manoharan M., Bennett C.F., Dean N.M. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26:1998;2016-2023.
119. Marti G., Egan W., Noguchi P., Zon G., Matsukura M., Broder S. Oligodeoxyribonucleotide phosphorothioate fluxes and localization in hematopoietic cells. Antisense Res Dev. 2:1992;27-39.
120. Meyer O., Kirpotin D., Hong K., Sternberg B., Park J.W., Woodle M.C., Papahadjopoulos D. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem. 273:1998;15621-15627.
121. Midoux P., Kichler A., Boutin V., Maurizot J.C., Monsigny M. Membrane permeabilization and efficient gene transfer by a peptide containing several histidines. Bioconjug Chem. 9:1998;260-267.
122. Miller K.J., Das S.K. Antisense oligonucleotides. strategies for delivery Pharm Sci Technol Today. 1:1998;377-386.
123. Mönkkönen J., Urrti A. Lipid fusion in oligonucleotide and gene delivery with cationic lipids. Adv Drug Delivery Rev. 34:1998;37-49.
124. Moore V.A., Dunnion D.J., Brown T., Irwin W.J., Akhtar S. Interaction of oligonucleotide-conjugates with the dipeptide transporter system in Caco-2 cells. Biochem Pharmacol. 53:1997;1223-1228.
125. Morishita R., Gibbons G., Ellison K.E., Nakajima M., Zhang L., Kaneda Y., Ogihara T., Dzau V.J. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci USA. 90:1993;8474-8478.
126. Morris M.C., Vidal P., Heitz F., Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25:1997;2730-2736.
127. Mortimer I., Tam P., MacLachlan I., Graham R.W., Saravolac E.G., Joshi P.B. Cationic lipid-mediated transfection of cells in culture requires mitotic activity. Gene Ther. 6:1999;403-411.
128. Murata M., Takahashi S., Kagiwada S., Suzuki A., Ohnishi S. pH-dependent membrane fusion and vesiculation of phospholipid large unilamellar vesicles induced by amphiphilic anionic and cationic peptides. Biochemistry. 31:1992;1986-1992.
129. Nakada Y., Fattal E., Foulquier M., Couvreur P. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm Res. 13:1996;38-43.
130. Nakai D., Seita T., Terasaki T., Iwasa S., Shoji Y., Mizushima Y., Sugiyama Y. Cellular uptake mechanism for oligonucleotides. involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human colorectal adenocarcinoma cell line, HCT-15 J Pharmacol Exp Ther. 278:1996;1362-1372.
131. Nestle F.O., Mitra R.S., Bennet C.F., Chan H., Nickoloff B.J. Cationic lipoid is not required for uptake and selective inhibitory activity of ICAM-1 phosporothioate antisense oligonucleotide in keratinocytes. J Invest Dermatol. 103:1994;569-575.
132. Noguchi A., Furuno T., Kawaura C., Nakanishi M. Membrane fusion plays an important role in gene transfection mediated by cationic liposomes. FEBS Lett. 433:1998;169-173.
133. Noonberg S.B., Garovoy M.R., Hunt C.A. Characteristics of oligonucleotide uptake in human keratinocyte cultures. J Invest Dermatol. 101:1993;727-731.
134. Normand-Sdiqui N., Akhtar S. Oligonucleotide delivery. uptake of rat transferrin receptor antibody (OX-26) conjugates into an in vitro immortalised cell line model of the blood-brain barrier Int J Pharm. 163:1998;63-71.
135. Ogata N., Otsuji T., Matsushima M., Kimoto T., Yamanaka R., Takabashi K., Wada M., Uyama M., Kaneda Y. Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system. Curr Eye Res. 18:1999;261-269.
136. Pardridge W.M., Boado R.J. Enhanced cellular uptake of biotinylated antisense oligonucleotides or peptide mediated by avidin, a cationic protein. FEBS Lett. 265:1991;30-35.
137. Parente R.A., Nir S., Szoka F.C. Jr. Mechanism of leakage of phospholipid vesicle contents induced by the peptide GALA. Biochemistry. 29:1990;8720-8728.
138. Pearson A.M., Rich A., Krieger M. Polynucleotide binding to macrophage scavenger receptors depends on the formation of base-quartet-stabilized four-stranded helices. J Biol Chem. 268:1993;3546-3554.
139. Persidis A. Antisense therapeutics. Nat Biotechnol. 17:1999;403-404.
140. Pichon C., Freulon I., Midoux P., Mayer R., Monsigny M., Roche A.C. Cytosolic and nuclear delivery of oligonucleotides mediated by an amphiphilic anionic peptide. Antisense Nucleic Acid Drug Dev. 7:1997;335-343.
141. Pichon C., Monsigny M., Roche A.C. Intracellular localization of oligonucleotides. influence of fixative protocols Antisense Nucleic Acid Drug Dev. 9:1999;89-93.
142. Pires P., Simoes S., Nir S., Gaspar R., Duzgunes N., deLima M.C.P. Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells. Biochim Biophys Acta. 1418:1999;71-84.
143. Politz J.C., Taneja K.L., Singer R.H. Characterization of hybridization between synthetic oligodeoxynucleotides and RNA in living cells. Nucleic Acids Res. 23:1995;4946-4953.
144. Puyal C., Milhaud P., Bienvenüe A., Philippot J.R. A new cationic liposome encapsulating genetic material. Eur J Biochem. 228:1995;697-703.
145. Quattrone A., Papucci L., Schiavone N., Mini E., Capaccioli S. Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids. Anticancer Drug Des. 9:1994;549-553.
146. Rappaport J., Hanss B., Kopp J.B., Copeland T.D., Bruggeman L.A., Coffman T.M., Klotman P.E. Transport of phosphorothioate oligonucleotides in kidney. implication for molecular therapy Kidney Int. 47:1995;1462-1469.
147. Reinis M., Damkova M., Korec E. Receptor-mediated transport of oligodeoxynucleotides into hepatic cells. J Virol Methods. 42:1993;99-105.
148. Rodriguez M., Noe V., Alemany C., Miralles A., Bemi V., Caragol I., Ciudad C.J. Effects of anti-sense oligonucleotides directed toward dihydrofolate reductase RNA in mammalian cultured cells. Int J Cancer. 81:1999;785-792.
149. Ropert C., Lavignon M., Dubernet C., Couvreur P., Malvy C. Oligonucleotides encapsulated in pH sensitive liposomes are efficient toward Friend retrovirus. Biochem Biophys Res Commun. 183:1992;879-885.
150. Ropert C., Malvy C., Couvreur P. Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes. mechanism of action Pharm Res. 10:1993;1427-1433.
151. Rump E.T., de Vrueh R.L., Sliedregt L.A., Biessen E.A., van Berkel T.J., Bijsterbosch M.K. Preparation of conjugates of oligodeoxynucleotides and lipid structures and their interaction with low-density lipoprotein. Bioconjug Chem. 9:1998;341-349.
152. Saijo Y., Perlaky L., Wang H., Busch H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res. 6:1994;243-249.
153. Schwab G., Chavany C., Duroux I., Goubin G., Lebeau J., Hélène C., Saison-Behmoaras T. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci USA. 91:1994;10460-10464.
154. Senior J.H., Trimble K.R., Maskiewicz R. Interaction of positively-charged liposomes with blood. implications for their application in vivo Biochim Biophys Acta. 1070:1991;173-179.
155. Shea R.G., Marsters J.C., Bischofberger N. Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates. Nucleic Acids Res. 18:1990;3777-3783.
156. Shoeman R.L., Hartig R., Huang Y.P., Grub S., Traub P. Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior. Antisense Nucleic Acid Drug Dev. 7:1997;291-308.
157. Shoji Y., Shimada J., Mizushima Y., Iwasawa A., Nakamura Y., Inouye K., Azuma T., Sakurai M., Nishimura T. Cellular uptake and biological effects of antisense oligodeoxynucleotide analogs targeted to herpes simplex virus. Antimicrob Agents Chemother. 40:1996;1670-1675.
158. Shoji Y., Norimatsu M., Shimada J., Mizushima Y. Limited use of cationic liposomes as tools to enhance the antiherpetic activities of oligonucleotides in vero cells infected with herpes simplex virus type 1. Antisense Nucleic Acid Drug Dev. 8:1998;255-263.
159. Sixou S., Szoka F.C., Green G.A., Giusti B., Zon G., Chin D.J. Intracellular oligonucleotide hybridization detected by fluorescence resonance energy transfer (FRET). Nucleic Acids Res. 22:1994;662-668.
160. Soni P.N., Brown D., Saffie R., Savage K., Moore D., Gregoriadis G., Dusheiko G.M. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection. Hepatology. 28:1998;1402-1410.
161. Spiller D.G., Tidd D.M. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res Dev. 5:1995;13-21.
162. Spiller D.G., Giles R.V., Broughton C.M., Grzybowski J., Ruddell C.J., Tidd D.M., Clark R.E. The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biological responses. Antisense Nucleic Acid Drug Dev. 8:1998;281-293. a.
163. Spiller D.G., Giles R.V., Grzybowski J., Tidd D.M., Clark R.E. Improving
164. Stein, C. A., & Krieg, A. M. (Eds.) (1998). Applied Antisense Oligonucleotide Technology. New York: Wiley-Liss.
165. Stein C.A., Tonkinson J.L., Zhang L., Yabukov L., Gervasoni J., Taub R., Rosenberg S. Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry. 32:1993;4855-4861.
166. Sternberg B., Sorgi F.L., Huang L. New structures in complex formation between DNA and cationic liposomes visualized by freeze-fracture electron microscopy. FEBS Lett. 356:1994;361-366.
167. Stewart A.J., Pichon C., Meunier L., Midoux P., Monsigny M., Roche A.C. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine. Mol Pharmacol. 50:1996;1487-1494.
168. Szklarczyk A.W., Kaczmarek L. Brain as a unique antisense environment. Antisense Nucleic Acid Drug Dev. 9:1999;105-116.
169. Szoka F.C., Xu Y., Zelphati O. How are nucleic acids released in cells from cationic lipid-nucleic acid complexes. J Liposome Res. 6:1996;567-587.
170. Takle G.B., Thierry A.R., Flynn S.M., Peng B.O., White L., Devonish W., Galbraith R.A., Goldberg A.R., George S.T. Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). Antisense Nucleic Acid Drug Dev. 7:1997;177-185.
171. Temsamani J., Guinot P. Antisense oligonucleotides. a new therapeutic approach Biotechnol Appl Biochem. 26:1997;65-71.
172. Thierry A.R., Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 20:1992;5691-5698.
173. Tomita N., Morishita R., Higaki J., Aoki M., Nakamura Y., Mikami H., Fukamizu A., Murakami K., Kaneda Y., Ogihara T. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension. 26:1995;131-136.
174. Tondelli L., Ricca A., Laus M., Lelli M., Citro G. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res. 26:1998;5425-5431.
175. Tonkinson J.L., Stein C.A. Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. 22:1994;4268-4275.
176. Uhlmann E., Ryte A., Peyman A. Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation. Antisense Nucleic Acid Drug Dev. 7:1997;345-350.
177. Vlassov V.V., Balakireva L.A., Yakubov L.A. Transport of oligonucleotides across natural and model membranes. Biochim Biophys Acta. 1197:1994;95-108.
178. Waelti E.R., Gluck R. Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int J Cancer. 77:1998;728-733.
179. Wagner E., Plank C., Zatloukal K., Cotten M., Birnstiel M.L. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes. toward a synthetic virus-like gene-transfer vehicle Proc Natl Acad Sci USA. 89:1992;7934-7938.
180. Walker I., Irwin W.J., Akhtar S. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res. 12:1995;1548-1553.
181. Walker S., Sofia M.J., Axelrod H.R. Chemistry and cellular aspects of cationic facial amphiphiles. Adv Drug Delivery Rev. 30:1998;61-71.
182. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci USA. 92:1995;3318-3322.
183. Wheeler C.J., Sukhu L., Yang G., Tsai Y., Bustamente C., Felgner P., Norman J., Manthorpe M. Converting an alcohol to an amine in a cationic lipid dramatically alters the co-lipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes. Biochim Biophys Acta. 1280:1996;1-11.
184. Williams S.A., Chang L., Buzby J.S., Suen Y., Cairo M.S. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth. Leukemia. 10:1996;1980-1989.
185. Wrobel I., Collins D. Fusion of cationic liposomes with mammalian cells occurs after endocytosis. Biochim Biophys Acta. 1235:1995;296-304.
186. Wu D., Boado R.J., Pardridge W.M. Pharmacokinetics and blood-brain barrier transport of 3-H-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J Pharmacol Exp Ther. 276:1996;206-211.
187. Wu G., Wu C. Specific inhibition of hepatitis B viral gene expression by targeted antisense oligonucleotides. J Biol Chem. 267:1992;12436-12439.
188. Wu-Pong S. Calcium-dependent oligonucleotide cellular uptake. Biochimie. 78:1996;33-38.
189. Wu-Pong S., Weiss T.L., Hunt C.A. Calcium-dependent cellular uptake of a c-myc antisense oligonucleotide. Cell Mol Biol. 40:1994;843-850.
190. Wu-Pong S., Bard J., Huffman J., Jimerson J. Oligonucleotide biological activity. relationship to the cell cycle and nuclear transport Biol Cell. 89:1997;257-261.
191. Wyman T.B., Nicol F., Zelphati O., Scaria P.V., Plank C., Szoka F.C. Jr. Design, synthesis, and characterization of cationic peptide that binds to nucleic acids and permeabilizes bilayers. Biochemistry. 36:1997;3008-3017.
192. Yakubov L.A., Deeva E.A., Zarytova V.F., Ivanova E.M., Ryte A.S., Yurchenko L.V., Vlassov V.V. Mechanism of oligonucleotide uptake by cells. involvement of specific receptors? Proc Natl Acad Sci USA. 86:1989;6454-6458.
193. Zabner J., Fasbender A.J., Moninger T., Poellinger K.A., Welsh M.J. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem. 270:1995;18997-19007.
194. Zamecnik P., Aghajanian J., Zamecnik M., Goodchild J., Witman G. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc Natl Acad Sci USA. 91:1994;3156-3160.
195. Zelphati O., Szoka F.C. Jr. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res. 13:1996;1367-1372. a.
196. Zelphati O., Szoka F.C. Jr. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides. a real or magic bullet? J Controlled Release. 41:1996;99-119. b.
197. Zelphati O., Szoka F.C. Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA. 93:1996;11493-11498. c.
198. Zelphati O., Uyechi L.S., Barron L.G., Szoka F.C. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta. 1390:1998;119-133.
199. Zhang Z., Smith J.A., Smyth A.P., Tang J.Y., Eisenberg W., Pari G.S. Inhibition of human cytomegalovirus DNA replication with a phosphorothioate cholesteryl-modified oligonucleotide is mediated by rapid cellular association and virus-facilitated nuclear localization. Antiviral Chem Chemother. 8:1997;255-264.
200. Zhou X.H., Huang L. DNA transfection mediated by cationic liposomes containing lipopolylysine - characterization and mechanism of action. Biochim Biophys Acta. 1189:1994;195-203.
201. Zimmer A., Aziz S.A., Gilbert M., Werner D., Noe C.R. Synthesis of cholesterol modified cationic lipids for liposomal drug delivery of antisense oligonucleotides. Eur J Pharm Biopharm. 47:1999;175-178.
202. Zobel H.P., Kreuter J., Werner D., Noe C.R., Kumel G., Zimmer A. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7:1997;483-493.
203. Zobel H.P., Stieneker F., Atmaca-Abdel Aziz S., Gilbert M., Werner D., Noe C.R., Kreuter J., Zimmer A. Evaluation of aminoalkylmethacrylate nanoparticles as colloidal drug carrier systems. II. Characterization of antisense oligonucleotides loaded copolymer nanoparticles. Eur J Pharm Biopharm. 48:1999;1-12.